Status:
COMPLETED
Jaktinib Hydrochloride Cream For Atopic Dermatitis
Lead Sponsor:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
PHASE2
Brief Summary
This study includes a dose escalation part and a dose extension part.
Detailed Description
In the dose-increasing part, a multicenter, dose-increasing, randomized, double-blind, placebo-parallel control design was adopted. Subjects were enrolled into different dose groups in sequence accord...
Eligibility Criteria
Inclusion
- 18\~ 65 years old (including boundary value), gender is not limited;
- Have a clinical diagnosis of atopic dermatitis;
- Have a PGA(Physician's Global Assessment) score of 2 (mild) or 3 (moderate) at baseline;
- The total area of atopic dermatitis is about 10%\~20% of the total area of the body surface at baseline.
Exclusion
- Evidence of certain skin conditions/infections at baseline;
- Have certain laboratory abnormalities at baseline;
- Females who are pregnant, breastfeeding, or are of childbearing potential not using highly effective contraception;
- Other conditions that the investigators considered inappropriate to participate in the trial.
Key Trial Info
Start Date :
October 14 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 8 2022
Estimated Enrollment :
107 Patients enrolled
Trial Details
Trial ID
NCT04435392
Start Date
October 14 2020
End Date
September 8 2022
Last Update
April 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China, 410008